SCHEMBL2090201

SCHEMBL2090201

[CH2]c1noc(-c2ccccc2CC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.39
TSHR P16473 2/20 0.39
HTT P42858 2/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
TP53 P04637 1/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPK1 P28482 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
ATR Q13535 1/20 0.38
CASP3 P42574 2/20 0.38
SENP8 Q96LD8 2/20 0.38
SENP7 Q9BQF6 2/20 0.38
SENP6 Q9GZR1 2/20 0.38
GPR55 Q9Y2T6 1/20 0.38
ATM Q13315 2/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090203 0.81 KMT2A (0.50) L3MBTL1TSHRHTTUSP2ALOX15
SCHEMBL6002674 0.81 L3MBTL1 (0.46) L3MBTL1TSHRHTTUSP2ALOX15
SCHEMBL95910 0.79 L3MBTL1 (0.47) L3MBTL1TSHRHTTUSP2ALOX15
SCHEMBL95911 0.78 NOTUM (0.57) L3MBTL1TSHRHTTUSP2ALOX15
SCHEMBL96972 0.74 ALDH1A1 (0.44) L3MBTL1TSHRHTTUSP2ALOX15
SCHEMBL5660757 0.73 RAB9A (0.60) L3MBTL1TSHRHTTUSP2TP53
SCHEMBL96973 0.73 TDP1 (0.44) L3MBTL1TSHRHTTUSP2ALOX15
SCHEMBL22556187 0.71 CYP2D6 (0.37) TP53ATRMAPTTRPA1MEN1
SCHEMBL30371288 0.71 CYP2D6 (0.37) TP53ATRMAPTTRPA1MEN1
SCHEMBL2096692 0.69 NR1H4 (0.63) L3MBTL1TSHRTP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 L3MBTL1 2575/4885TSHR 162/4885HTT 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.